| Previous Close | 32.57 |
| Open | 33.05 |
| Bid | 33.04 x 0 |
| Ask | 33.14 x 0 |
| Day's Range | 32.77 - 33.53 |
| 52 Week Range | 32.77 - 33.53 |
| Volume | 5,350 |
| Avg. Volume | 5,400 |
| Market Cap | 1.3B |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Zymeworks Reports 2020 Year-End Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and provided a summary of recent business and clinical highlights.
- Business Wire
Zymeworks to Participate in Upcoming Investor Conferences and Events
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor conferences.
- Business Wire
Zymeworks Expands Commercial Team and Creates New R&D Role
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that James Priour, former Senior Vice President, Commercial, has been promoted to Chief Commercial Officer and named to the Company’s Executive Committee. The Commercial team also recently expanded its leadership with the addition of Manny Duenas as Vice President, Global Value & Access. Zymeworks also announced that John Babcook, former head of Discovery Research, will move into a newly created Distinguished Fellow role. Senior Vice President of Research Guowei Fang, Ph.D. will take on leadership of Discovery Research.
